Source: International Congress 2018 – Pulmonary hypertension: therapy
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Sandoval Zarate (Mexico City, Mexico), R. Teijeiro Paradis (Mexico City, Mexico), T. Pulido Zamudio (Mexico City, Mexico), N. Zayas Hernadnez (Mexico City, Mexico), L. Del Valle (Mexico City, Mexico), F. Massó (Mexico City, Mexico), H. Gonzalez (Mexico City, Mexico), C. Sisniega (Mexico City, Mexico), G. Pastelin (Mexico City, Mexico). Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension. 3047

Member's Comments

No comment yet.

Related content which might interest you: Increased renin-angiotensin-aldosteron system activity in lungs of patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Polymorphisms in angiotensin converting enzyme gene are associated with risk of development of and disease severity in scleroderma-related pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Double combination therapy in patients with pulmonary arterial hypertension associated with congenital heart defects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease Source: Eur Respir Rev 2009; 18: 154-161 Year: 2009 Changing demographics of pulmonary arterial hypertension in congenital heart disease Source: Eur Respir Rev 2010 19: 308-313 Year: 2010 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity Source: Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019 Year: 2020 The effect of 12 months Bosentan treatment on congenital heart disease associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006 The endothelin-receptor antagonist bosentan for the treatment of pulmonary arterial hypertension (PAH) associated with congenital heart defects (CHD) Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011 Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH) Source: Eur Respir J 2006; 28: Suppl. 50, 427s Year: 2006